VEGFR-2, FGFR2, and PDGFRα (VEGFR-2, FGFR2, PDGFRα)

Vascular endothelial growth factor receptor 2 is a glycoprotein transmembrane receptor (230 kDa mature form) encoded by the *KDR* gene on chromosome 4q11-12. It is the principal receptor for VEGF-A and mediates critical signaling for angiogenesis and vascular permeability in endothelial and some precursor cells. VEGFR-2 activation drives the growth of new blood vessels in normal development and in disease, particularly tumors, making it a major target for anti-angiogenic cancer therapies[1][2][3][4][7]. Fibroblast growth factor receptor 2 is a transmembrane receptor tyrosine kinase involved in developmental processes and angiogenesis. FGFR2 is activated by binding to fibroblast growth factors (e.g., FGF-2), driving cell proliferation and differentiation. Dysregulation contributes to tumorigenesis and skeletal disorders, making it a therapeutic target, especially in certain cancers[5][6]. Platelet-derived growth factor receptor alpha is a transmembrane receptor tyrosine kinase primarily expressed in mesenchymal cells. It is activated by PDGF ligands, mediating cell proliferation, survival, and migration. Aberrant PDGFRα signaling is implicated in cancer and fibrotic diseases, and inhibitors are used therapeutically in selected tumor types[5][6]. Context: These three RTKs often co-activate or cooperate in tumor angiogenesis, pericyte recruitment, and vessel stabilization[5]. Drugs may target one or more of these kinases for maximal anti-angiogenic effect or to overcome drug resistance in cancers where angiogenesis is driven by multiple growth factor pathways[6]. No spelling errors or misname detected in the provided target; listing targets together is common in multi-kinase inhibition strategies. Overall, VEGFR-2, FGFR2, and PDGFRα are well-established, clinically validated therapeutic targets belonging to the receptor tyrosine kinase family, primarily involved in angiogenesis and cancer, and are each individually targeted by approved anti-cancer drugs[1][5][6].

Other names

Kinase insert domain receptor (KDR)fetal liver kinase 1 (Flk-1, mouse)VEGF receptor 2CD332CD140a

VEGFR-2: Inhibition of receptor autophosphorylation and downstream signal transduction by targeting the ATP-binding site of the kinase domain. Blockade of ligand binding (VEGF-A, VEGF-C, VEGF-D). FGFR2: Inhibition of FGFR2 kinase activity, blocking phosphorylation and signal transduction. PDGFRα: Inhibition of PDGFRα kinase activity, preventing downstream signaling.